Nothing Special   »   [go: up one dir, main page]

CN113474343A - 作为ret抑制剂的吡唑并吡啶类化合物及其应用 - Google Patents

作为ret抑制剂的吡唑并吡啶类化合物及其应用 Download PDF

Info

Publication number
CN113474343A
CN113474343A CN202080009389.XA CN202080009389A CN113474343A CN 113474343 A CN113474343 A CN 113474343A CN 202080009389 A CN202080009389 A CN 202080009389A CN 113474343 A CN113474343 A CN 113474343A
Authority
CN
China
Prior art keywords
compound
added
mol
alkyl
variables
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080009389.XA
Other languages
English (en)
Other versions
CN113474343B (zh
Inventor
王健松
陈正霞
罗志波
戴美碧
张杨
陈曙辉
鲍颖霞
王玮
谢周凡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Baiyunshan Pharmaceutical Holdings Co ltd Baiyunshan Pharmaceutical General Factory
Original Assignee
Guangzhou Baiyunshan Pharmaceutical Holdings Co ltd Baiyunshan Pharmaceutical General Factory
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Baiyunshan Pharmaceutical Holdings Co ltd Baiyunshan Pharmaceutical General Factory, Medshine Discovery Inc filed Critical Guangzhou Baiyunshan Pharmaceutical Holdings Co ltd Baiyunshan Pharmaceutical General Factory
Publication of CN113474343A publication Critical patent/CN113474343A/zh
Application granted granted Critical
Publication of CN113474343B publication Critical patent/CN113474343B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明公开了一系列吡唑并吡啶类化合物，及其在制备治疗作为RET激酶抑制剂中的应用。具体公开了式(I)所示化合物或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN202080009389.XA 2019-04-03 2020-04-03 作为ret抑制剂的吡唑并吡啶类化合物及其应用 Active CN113474343B (zh)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
CN2019102702891 2019-04-03
CN201910270289 2019-04-03
CN2019104498752 2019-05-27
CN201910449875 2019-05-27
CN2019104496297 2019-05-27
CN201910449629 2019-05-27
CN2019104849778 2019-06-04
CN201910484977 2019-06-04
CN201910893692X 2019-09-20
CN201910892514 2019-09-20
CN201910893692 2019-09-20
CN201910892976 2019-09-20
CN2019108929767 2019-09-20
CN2019108925145 2019-09-20
CN2019110862178 2019-11-08
CN201911086217 2019-11-08
CN201911105397 2019-11-13
CN201911105397X 2019-11-13
CN2019111102016 2019-11-13
CN201911110201 2019-11-13
CN202010023277 2020-01-09
CN2020100232771 2020-01-09
PCT/CN2020/083318 WO2020200316A1 (zh) 2019-04-03 2020-04-03 作为ret抑制剂的吡唑并吡啶类化合物及其应用

Publications (2)

Publication Number Publication Date
CN113474343A true CN113474343A (zh) 2021-10-01
CN113474343B CN113474343B (zh) 2024-01-23

Family

ID=72664966

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080009389.XA Active CN113474343B (zh) 2019-04-03 2020-04-03 作为ret抑制剂的吡唑并吡啶类化合物及其应用

Country Status (6)

Country Link
US (1) US20220220104A1 (zh)
EP (1) EP3950685A4 (zh)
JP (1) JP7291243B2 (zh)
CN (1) CN113474343B (zh)
BR (1) BR112021019643A2 (zh)
WO (1) WO2020200316A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112368283A (zh) * 2019-05-14 2021-02-12 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN114072404A (zh) * 2019-07-12 2022-02-18 首药控股(北京)股份有限公司 Ret选择性抑制剂及其制备方法和用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021088911A1 (zh) * 2019-11-08 2021-05-14 杭州邦顺制药有限公司 作为ret激酶抑制剂的3、6二氮杂双环[3.1.1]庚烷衍生物
CN112851664B (zh) * 2019-11-12 2024-03-29 浙江海正药业股份有限公司 吡唑[1,5-a]吡啶-3-腈化合物及其在医药上的用途
CN112939967B (zh) * 2019-12-11 2024-08-27 深圳众格生物科技有限公司 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
AU2020410900B2 (en) * 2019-12-27 2024-06-13 Tyk Medicines, Inc. Compound used as RET kinase inhibitor and application thereof
AU2021326917B2 (en) * 2020-08-20 2024-08-29 Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. Heteroaromatic ring compound as ret kinase inhibitor, and preparation and use thereof
CN115867273A (zh) * 2020-09-29 2023-03-28 广州白云山医药集团股份有限公司白云山制药总厂 吡啶并吡唑类化合物的晶型及其制备方法
CA3198559A1 (en) * 2020-11-13 2022-05-19 Hua Dong Crystal form of free base of inhibitor containing bicyclic ring derivative and preparation method and application of crystal form
CN112679494B (zh) * 2020-12-24 2023-05-16 贵州民族大学 一种吡唑并[1,5-a]吡啶衍生物的制备方法
CN113816955B (zh) * 2021-09-29 2022-08-26 厦门云凡医药科技有限公司 一种ret激酶抑制剂中间体及其制备方法
WO2024030968A1 (en) * 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049127A1 (en) * 2016-09-08 2018-03-15 Sabila Biosciences Llc 1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions
US20180133200A1 (en) * 2016-10-10 2018-05-17 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CN108349969A (zh) * 2015-07-16 2018-07-31 阵列生物制药公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡啶化合物
CN109195972A (zh) * 2016-04-15 2019-01-11 癌症研究科技有限公司 作为ret激酶抑制剂的杂环化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CN111285886B (zh) 2018-12-06 2023-04-11 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]吡啶化合物及包含该化合物的组合物及其用途
AU2019392232A1 (en) 2018-12-07 2021-05-20 Sunshine Lake Pharma Co., Ltd. RET inhibitors, pharmaceutical compositions and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349969A (zh) * 2015-07-16 2018-07-31 阵列生物制药公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡啶化合物
CN109195972A (zh) * 2016-04-15 2019-01-11 癌症研究科技有限公司 作为ret激酶抑制剂的杂环化合物
WO2018049127A1 (en) * 2016-09-08 2018-03-15 Sabila Biosciences Llc 1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions
US20180133200A1 (en) * 2016-10-10 2018-05-17 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112368283A (zh) * 2019-05-14 2021-02-12 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN112368283B (zh) * 2019-05-14 2023-02-17 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN115974897A (zh) * 2019-05-14 2023-04-18 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN116444515A (zh) * 2019-05-14 2023-07-18 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN114072404A (zh) * 2019-07-12 2022-02-18 首药控股(北京)股份有限公司 Ret选择性抑制剂及其制备方法和用途
CN114072404B (zh) * 2019-07-12 2023-09-15 首药控股(北京)股份有限公司 Ret选择性抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
EP3950685A4 (en) 2022-12-14
US20220220104A1 (en) 2022-07-14
JP2022529209A (ja) 2022-06-20
CN113474343B (zh) 2024-01-23
JP7291243B2 (ja) 2023-06-14
WO2020200316A1 (zh) 2020-10-08
BR112021019643A2 (pt) 2021-12-07
EP3950685A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
CN113474343A (zh) 作为ret抑制剂的吡唑并吡啶类化合物及其应用
CN114040914B (zh) 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
CN104507926B (zh) 丝氨酸/苏氨酸激酶抑制剂
WO2022170999A1 (zh) 吡啶[4，3-d]嘧啶类化合物
CN115298174A (zh) 嘧啶并杂环类化合物及其应用
CN113801114B (zh) 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
WO2022171147A1 (zh) 嘧啶并芳香环类化合物
TWI676622B (zh) 作為rho激酶抑制劑的異喹啉磺醯衍生物
CN111788205B (zh) 吡唑并嘧啶衍生物及其用途
CN117642407A (zh) 一种含氮杂环化合物、其制备方法、中间体及应用
CN105073715B (zh) 二氢哒嗪‑3,5‑二酮衍生物
JP7168149B2 (ja) Ｆｇｆｒ阻害剤としてのピラジン－２（１ｈ）－オン系化合物
CN107793411A (zh) 异喹啉酮类化合物及作为抗病毒药物的应用
CN105263935A (zh) 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其作为MGLUR2受体的负性别构调节物的用途
WO2023138583A1 (zh) 杂环类化合物、药物组合物及其应用
CN105085525B (zh) 作为rho激酶抑制剂的异喹啉磺酰衍生物
CN115867346A (zh) 激酶抑制剂
CN114728967A (zh) 作为jak抑制剂的三并杂环类化合物及其应用
CN118355019A (zh) 苯并嘧啶类化合物及其应用
TWI844242B (zh) 橋環取代的雜芳基並吡喃類衍生物及其應用
JP2024528021A (ja) 新規なｐａｒｐ７阻害剤及びその使用
CN112955453B (zh) 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
CN111315750B (zh) 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
WO2023241618A1 (zh) 氨基嘧啶类化合物及其应用
WO2023208127A1 (zh) 杂芳基取代的双环化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220706

Address after: Baiyun District of Guangzhou City, Guangdong province 510515 street and with the Cloud Road No. 88

Applicant after: GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS Co.,Ltd. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY

Address before: Baiyun District of Guangzhou City, Guangdong province 510515 street and with the Cloud Road No. 88

Applicant before: GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS Co.,Ltd. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant